Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance

Cell Biochemistry and Function

Volumn 29, Issue 5, 2011, Pages 351-355

  Virag, Piroska ^a   Brie, Ioana ^a   Fischer Fodor, Eva ^a   Perde Schrepler, Maria ^a   Tatomir, Corina ^a   Balacescu, Ovidiu ^a   Irimie, Alexandru ^b   Postescu, Ion Dan ^a  

^a Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Apoptosis; Chemoresistance; Cytotoxicity; DNA damage; Oxaliplatin

Indexed keywords

OXALIPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG STRUCTURE; GENOTOXICITY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOTOXINS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; MUTAGENICITY TESTS; ORGANOPLATINUM COMPOUNDS;

EID: 79960095172     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1754     Document Type: Article

References (23)

1. Mathé G, Kidani Y, Triana K, et al. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother 1986; 40: 372-376.
2. Foltinová V, Švihálková-Šindlerová L, Horváth V, et al. Mechanisms of effects of platinum (II) and (IV) complexes. Comparison of cisplatin and oxaliplatin with satraplatin and LA-12. New Pt IV based drugs. A minireview. Scr Med (BRNO) 2008; 81(2): 105-116.
3. Luo FR, Yen TY, Wyrick SD, Chaney SG. High-performance liquid chromatographic separation and biotransformation products of oxaliplatin. J Chromatogr Sci Appl 1999; 724: 345-356.
4. Mauldin SK, Gibbons G, Wyrick SD, Chaney SG. Intracellular biotransformation of platinum compounds with the 1, 2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 1988; 48: 5136-5144.
5. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002; 59: 1914-1927.
6. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000; 6: 1205-1218.
7. Butour JL, Mazard AM, Macquet JP. Kinetics of the reaction of cis-platinum compounds with DNA in vitro. Biochem Biophys Res Commun 1985; 133: 347-353.
8. Woynarowski JM, Chapman WG, Napier C Raymond E. Oxaliplatin effects on naked and intracellular DNA. Proc Am Assoc Cancer Res 1997; 38: 311.
9. Richon VM, Schulte N, Eastman A. Multiple mechanisms of resistance to cis diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 1987; 47: 2056-2061.
10. Kelley SL, Basu A, Teicher BA Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-1815.
11. Barltrop JA, Owen TC, Cory AH, Cory JG. 5-(3-carboxymethoxyphenyl)-2-(4, 5-dimethylthiazoly)-3-(4-sulfophenyl) tetrazolium, inner salt (MTS) and related analogs of 3-(4, 5-dimethylthiazolyl)-2, 5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans as cell-viability indicators. Bioorg Med Chem Lett 1991; 1: 611-614.
12. Koopman G, Reutlingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
13. Hovhannisyan GG, Haroutunyan TS, Arutyunyan RM. Evaluation of cisplatin-DNA crosslinks formation with UV-C application by the alkaline comet-assay. Exp Oncol 2004; 26(3): 240-242.
14. Tice RR, Agurell E, Anderson D, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000; 35: 206-221.
15. Collins AR, Dobson VL, Dušinská M, Kennedy G, Stětina R. The comet assay: what it can really tell us? Mutat Res 1997; 375: 183-193.
16. Andre T, de Gramont A. An overview of adjuvant systemic chemotherapy for colon cancer. Clin Colorectal Cancer 2004; 4: S22-S28.
17. Smorenburg CH, Peters GJ, Van Groeningen CJ, et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006; 17: 35-42.
18. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004; 91: 1931-1946.
19. Temmink OH, Hoebe EK, van der Born K, Ackland SP, Fukushima M, Peters GJ. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 2007; 96: 231-240.
20. Martelli L, Di Mario F, Ragazzi E, et al. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem Pharmacol 2006; 72: 693-700.
21. Unger FT, Klasen HA, Tchartchian G, de Wilde RL, Witte I. DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer 2009; 9: 359.
22. Herrera M, Dominguez G, Garcia JM, et al. Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay. Clin Cancer Res 2009; 15(17): 5466-5472.
23. Almeida GM, Duarte TL, Steward WP, Jones GD. Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair 2006; 5: 219-225.